title: A new look at dry eye disease and its treatment.
abstract: This review examines the impact of moderate to severe dry eye disease on daily life and medical-resource utilization. The results suggest that current treatment paradigms can lead to unacceptable costs in both quality of life and progressive use of healthcare resources. Evidence linking this disease to T-cell-mediated inflammatory processes lays the foundation for understanding the clinical benefits of topical cyclosporine, an immunomodulatory and anti-inflammatory agent.
authors.affiliation: HealthPartners Medical Group, Minneapolis, Regions Hospital, St. Paul, MN 55101, USA.
authors.forename: J D
authors.initials: JD
authors.lastname: Nelson
authors.forename: H
authors.initials: H
authors.lastname: Helms
authors.forename: R
authors.initials: R
authors.lastname: Fiscella
authors.forename: Y
authors.initials: Y
authors.lastname: Southwell
authors.forename: J D
authors.initials: JD
authors.lastname: Hirsch
mesh_terms: D000328:Adult; D000368:Aged; D017281:Cost of Illness; D015352:Dry Eye Syndromes / Q000191:economics / Q000453:epidemiology / Q000276:immunology / Q000628:therapy; D005260:Female; D006801:Humans; D007249:Inflammation / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D014481:United States / Q000453:epidemiology